Trenimon

MedChemExpress

Cat. No.:	HY-105740		•	
CAS No.:	68-76-8		Q	/
Molecular Formula:	$C_{12}H_{13}N_{3}O_{2}$			_N·
Molecular Weight:	231.25		li ì	-
Target:	DNA/RNA Synthesis			``
Pathway:	Cell Cycle/DNA Damage	\sum^{N}	Ĭ	N-
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.	V	0	
	CAS No.: Molecular Formula: Molecular Weight: Target: Pathway:	CAS No.:68-76-8Molecular Formula: $C_{12}H_{13}N_3O_2$ Molecular Weight:231.25Target:DNA/RNA SynthesisPathway:Cell Cycle/DNA DamageStorage:Please store the product under the recommended conditions in the Certificate of	CAS No.: 68-76-8 Molecular Formula: $C_{12}H_{13}N_3O_2$ Molecular Weight: 231.25 Target: DNA/RNA Synthesis Pathway: Cell Cycle/DNA Damage Storage: Please store the product under the recommended conditions in the Certificate of	CAS No.: 68-76-8 Molecular Formula: $C_{12}H_{13}N_3O_2$ Molecular Weight: 231.25 Target: DNA/RNA Synthesis Pathway: Cell Cycle/DNA Damage Storage: Please store the product under the recommended conditions in the Certificate of

Product Data Sheet

BIOLOGICAL ACTI			
Description	Trenimon is a compound with anti-cancer effects. Trenimon shows mutagenic actions in many species by inducing point and chromosomal mutations, sister-chromatid exchanges, recombination phenomena and phage induction. Trenimon can be used for the research of cancer ^{[1][2][3][4]} .		
In Vitro	Trenimon (0.17 mM) penetrates readily into mouse lymphoma cells in vitro ^[1] . Trenimon (0.17 nM; 5 min-16 h) time-denpendently reduces the priming activity of DNA ^[2] . Trenimon (1 nM-10 μM; 10-20 min) leds HeLa cells death after 2 weeks with a dose of 10 μM and dose-dependently suppresses mitosis in cells ^[3] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.		
In Vivo	Trenimon (0.25 mg/kg; i.p. once) rapidly depresseas of the cellular elements of the peripheral blood (granulocytes, lymphocytes, reticulocytes, platelets and erythrocytes), and reduces the cell number of bone marrow ^[4] . Trenimon (0.03 mg/kg; i.v. once per week for 52 weeks) shows an cancerogenic effect in vivo ^[4] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.		
	Animal Model:	BR 46 male rats ^[4]	
	Dosage:	0.03 mg/kg	
	Administration:	Intravenous injection; 0.03 mg/kg once per week for 52 weeks	
	Result:	Showed an cancerogenic effect and 24% animals developed malign tumors, and showed a induction time of the tumors is 16 months.	

REFERENCES

[1]. Linford JH. 2,3,5-Tris-ethylenimino-1,4-benzoquinone (Trenimon): some chemical and biological properties. Chem Biol Interact. 1973 Mar;6(3):149-68.

[2]. GRUNICKE H, et al. THE EFFECTS OF THE ALKYLATING CYTOSTATIC AGENT, 2,3,5-TRISETHYLENEIMINO-BENZOQUINONE-1,4(TRENIMON), ON THE PRIMING ABILITY OF DNA FROM MOUSE-ASCITES-TUMOR CELLS IN THE RNA-POLYMERASE-SYSTEM. Biochem Biophys Res Commun. 1965 Feb 3;18:319-24.

[3]. Wegehaupt S, Sehrbundt HJ. Cytologische Untersuchungen an HeLa-Zellen nach kurzfristigen 2,3,5-Trisathyleniminobenzochinon-1,4-Gaben (Trenimon-R) [Cytologic studies on HeLa cells following short-spaced doses of 2,3,5-trisethyleniminobenzoquinone-1,4 (Trenimon-R)]. Naturwissenschaften. 1967 Mar;54(5):123. German.

[4]. Obe G, Beek B. Trenimon: biochemical, physiological and genetic effects on cells and organisms. Mutat Res. 1979 Mar;65(1):21-70.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA